Prot #KRT-232-101: An Open-Label, Phase 2a/2b Study of KRT-232 in Subjects With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post-PV-MF), Or Post–Essential Thrombocythemia MF (Post–ET-MF) Who Have Failed Prior Treatment with a JAK Inhibitor

Project: Research project

Project Details

StatusActive
Effective start/end date4/15/194/15/22

Funding

  • PRA Health Sciences (Prot #KRT-232-101)
  • Kartos Therapeutics, Inc. (Prot #KRT-232-101)